ScinoPharm Taiwan Ltd (台灣神隆), which makes active pharmaceutical ingredients (APIs), said it expects adverse market conditions to continue to affect its business this year.
The company’s core business of exporting generic drugs has been hit by falling prices as a series of mergers and acquisitions (M&A) raised the bargaining power of US-based drug distributors through joint procurements, it said.
The company also said it expects continued headwinds from a stronger New Taiwan dollar, after sales last year declined 6 percent due to exchange-rate fluctuations.
ScinoPharm on Friday reported that net income last year fell 36 percent annually to NT$422 million (US$14.4 million), with sales dipping 13 percent to NT$3.52 billion.
Earnings per share were NT$0.53, it said.
The company’s clients have trimmed their orders for Paclitaxel, a chemotherapy for ovarian and breast cancer, amid an inventory correction, while shipments of other major generic drugs were delayed due to the replacement and integration of product lines and factories in the wake of M&As among clients, ScinoPharm said.
However, the company said that manufacturing contracts for newly approved antibiotics Baxdela and Vibativ helped offset some of the lost sales in generic drugs.
ScinoPharm said that its partnership with Baxter International Inc has begun to bear fruit as it expands into the generic oncology injectibles market.
The partnership with the US-based Baxter enables the companies to jointly develop formulations while sharing the risks and profits, ScinoPharm said.
Royalties from its anticoagulant Fondaparinux last year increased significantly from a year earlier, it added.
As for the operations of its Changshu plant in China’s Jiangsu Province, ScinoPharm said that the increase in the plant’s revenue contribution has not been as fast as expected due to the rapidly changing environmental safety and health-related laws in China.
The company will continue with its strategy of integrating niche APIs and venturing into formulation, chief executive officer Fred Chen (陳勇發) said in a statement.
In terms of product selection, the company aims to prioritize the distribution of vertically integrated injectables, including small molecule injections and peptide APIs, Chen said.
Regarding the contract research and manufacturing business, the company is seeking new projects in targeted therapy and orphan drugs that have shorter development cycles, he said.
IN THE AIR: While most companies said they were committed to North American operations, some added that production and costs would depend on the outcome of a US trade probe Leading local contract electronics makers Wistron Corp (緯創), Quanta Computer Inc (廣達), Inventec Corp (英業達) and Compal Electronics Inc (仁寶) are to maintain their North American expansion plans, despite Washington’s 20 percent tariff on Taiwanese goods. Wistron said it has long maintained a presence in the US, while distributing production across Taiwan, North America, Southeast Asia and Europe. The company is in talks with customers to align capacity with their site preferences, a company official told the Taipei Times by telephone on Friday. The company is still in talks with clients over who would bear the tariff costs, with the outcome pending further
NEGOTIATIONS: Semiconductors play an outsized role in Taiwan’s industrial and economic development and are a major driver of the Taiwan-US trade imbalance With US President Donald Trump threatening to impose tariffs on semiconductors, Taiwan is expected to face a significant challenge, as information and communications technology (ICT) products account for more than 70 percent of its exports to the US, Chung-Hua Institution for Economic Research (CIER, 中華經濟研究院) president Lien Hsien-ming (連賢明) said on Friday. Compared with other countries, semiconductors play a disproportionately large role in Taiwan’s industrial and economic development, Lien said. As the sixth-largest contributor to the US trade deficit, Taiwan recorded a US$73.9 billion trade surplus with the US last year — up from US$47.8 billion in 2023 — driven by strong
AI: Softbank’s stake increases in Nvidia and TSMC reflect Masayoshi Son’s effort to gain a foothold in key nodes of the AI value chain, from chip design to data infrastructure Softbank Group Corp is building up stakes in Nvidia Corp and Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), the latest reflection of founder Masayoshi Son’s focus on the tools and hardware underpinning artificial intelligence (AI). The Japanese technology investor raised its stake in Nvidia to about US$3 billion by the end of March, up from US$1 billion in the prior quarter, regulatory filings showed. It bought about US$330 million worth of TSMC shares and US$170 million in Oracle Corp, they showed. Softbank’s signature Vision Fund has also monetized almost US$2 billion of public and private assets in the first half of this year,
POWELL SUCCESSOR: US Fed Governor Adriana Kugler’s resignation gives Donald Trump an opening on the board, potentially accelerating his decision on the next chair US President Donald Trump suddenly has a chance to fill an opening at the US Federal Reserve earlier than expected, after Fed Governor Adriana Kugler announced her resignation on Friday. It might also force him to pick the next Fed chair months sooner than he had anticipated. “The ball is now in Trump’s court,” LH Meyer/Monetary Policy Analytics Inc economist Derek Tang said. “Trump is the one who’s been putting pressure on the Fed to do this and that, and Trump says he wants to have his own people on. So now he has the opportunity.” Kugler’s exit unfolds amid unprecedented public pressure
RSS